Package Leaflet: Information for the User
Efficib 50mg/850mg film-coated tablets
Efficib 50mg/1000mg film-coated tablets
sitagliptin/metformin hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Efficib contains two different medicines called sitagliptin and metformin.
They work together to control blood sugar levels in adult patients with a form of diabetes called “type 2 diabetes mellitus”. This medicine helps increase the amount of insulin produced after a meal and reduces the amount of sugar produced by your body.
Together with diet and exercise, this medicine helps lower your blood sugar level. This medicine can be used alone or with certain other medicines for diabetes (insulin, sulfonylureas, or glitazones).
What is type 2 diabetes?
Type 2 diabetes is a disease in which your body does not produce enough insulin and the insulin your body produces does not work as well as it should. Your body may also produce too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, such as heart disease, kidney disease, blindness, and amputations.
Do not take Efficib
Do not take Efficib if you are affected by any of the above circumstances and consult your doctor about other ways to control your diabetes. If you are not sure, consult your doctor, pharmacist, or nurse before taking Efficib.
Warnings and precautions
Cases of pancreatitis have been reported in patients treated with Efficib (see section 4).
If you notice blisters on your skin, it may be a sign of a disease called bullous pemphigoid. Your doctor may ask you to stop taking Efficib.
Risk of lactic acidosis
Efficib may cause a very rare but very serious side effect called lactic acidosis, especially if your kidneys do not work properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, severe infections, prolonged fasting, or alcohol consumption, dehydration (see more information below), liver problems, and any medical condition in which a part of the body has a reduced oxygen supply (such as acute and severe heart disease).
If any of the above applies to you, consult your doctor for further instructions.
Consult your doctor promptly to advise you on how to proceed if:
Stop taking Efficib for a short period if you have a condition that may be associated with dehydration(significant loss of body fluids), such as severe vomiting, diarrhea, fever, heat exposure, or if you drink less fluid than usual. Consult your doctor for further instructions.
Stop taking Efficib and contact a doctor or the nearest hospital immediately if you experience any symptoms of lactic acidosis, as this condition can lead to a coma.
Symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency and should be treated in a hospital.
Consult your doctor or pharmacist before starting to take Efficib:
If you need to undergo major surgery, you should stop taking Efficib during the procedure and for some time after. Your doctor will decide when you should stop taking Efficib and when you can restart it.
If you are not sure if you are affected by any of the above circumstances, consult your doctor or pharmacist before taking Efficib.
During treatment with Efficib, your doctor will check your kidney function at least once a year or more frequently if you are an elderly person and/or if your kidney function is worsening.
Children and adolescents
Children and adolescents under 18 years of age should not use this medicine. It is not effective in children and adolescents between 10 and 17 years of age. It is not known if this medicine is safe and effective when used in children under 10 years of age.
Other medicines and Efficib
If you need to be given an injection of a contrast agent containing iodine into your bloodstream, for example, in the context of a radiograph or scan, you should stop taking Efficib before the injection or at the time of the injection. Your doctor will decide when you should stop taking Efficib and when you can restart it.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dose of Efficib. It is especially important to mention the following:
Taking Efficib with alcohol
Avoid excessive alcohol consumption while taking Efficib, as this may increase the risk of lactic acidosis (see section “Warnings and precautions”).
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not take this medicine during pregnancy. Do not take this medicine if you are breast-feeding. See section 2, Do not take Efficib.
Driving and using machines
The effect of this medicine on your ability to drive or use machines is negligible or non-existent. However, cases of dizziness and drowsiness have been reported during treatment with sitagliptin, which may affect your ability to drive or use machines.
Taking this medicine with sulfonylureas or insulin may cause hypoglycemia, which may affect your ability to drive or use machines or work without a secure support.
Efficib contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially, “sodium-free”.
Follow the instructions for taking this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist again.
You should continue with the diet recommended by your doctor during treatment with this medicine and be careful to distribute your carbohydrate intake evenly throughout the day.
It is unlikely that treatment with this medicine alone will cause you to have abnormally low blood sugar levels (hypoglycemia). Hypoglycemia may occur when this medicine is taken with a medicine that contains a sulfonylurea or with insulin, so your doctor may consider it necessary to reduce the dose of your sulfonylurea or insulin.
If you take more Efficib than you should
If you take more of the prescribed dose of this medicine, contact your doctor immediately. Go to the hospital if you have symptoms of lactic acidosis such as feeling cold or unwell, nausea or vomiting, stomach pain, unexplained weight loss, muscle cramps, or rapid breathing (see section “Warnings and precautions”).
If you forget to take Efficib
If you forget to take a dose, take it as soon as you remember. If you do not remember until the time of your next dose, skip the missed dose and continue with your usual treatment. Do not take a double dose of this medicine.
If you stop taking Efficib
Keep taking this medicine for as long as your doctor tells you to, to help control your blood sugar levels. Do not stop taking this medicine without first talking to your doctor. If you stop taking Efficib, your blood sugar levels may increase again.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
STOP taking Efficib and contact a doctor immediatelyif you notice any of the following serious side effects:
Efficib may cause a very rare but very serious side effect called lactic acidosis (see section “Warnings and precautions”). If this happens to you, stop taking Efficib and contact a doctor or the nearest hospital immediately, as lactic acidosis can lead to a coma.
If you have a severe allergic reaction (frequency not known), including skin rash, hives, blisters on the skin/exfoliative skin conditions, and swelling of the face, lips, tongue, and throat that may cause difficulty breathing or swallowing, stop taking this medicine and consult your doctor immediately. Your doctor will prescribe a medicine to treat the allergic reaction and change your medicine for diabetes treatment.
Some patients who took metformin have experienced the following side effects after starting treatment with sitagliptin:
Common (may affect up to 1 in 10 people): low blood sugar, nausea, gas, vomiting
Uncommon (may affect up to 1 in 100 people): stomach pain, diarrhea, constipation, drowsiness
Some patients have experienced diarrhea, nausea, gas, constipation, stomach pain, or vomiting when starting treatment with the combination of sitagliptin and metformin (frequency classified as common).
Some patients have experienced the following side effects when taking this medicine with a sulfonylurea such as glimepiride:
Very common (may affect more than 1 in 10 people): low blood sugar levels
Common: constipation
Some patients have experienced the following side effects when taking this medicine with pioglitazone:
Common: swelling of hands or feet
Some patients have experienced the following side effects when taking this medicine with insulin:
Very common: low blood sugar levels
Uncommon: dry mouth, headache
Some patients have experienced the following side effects during clinical studies while taking sitagliptin alone (one of the medicines that Efficib contains) or during use after approval of Efficib or sitagliptin alone or with other diabetes medicines:
Common: low blood sugar levels, headache, upper respiratory tract infection, nasal congestion or runny nose, and sore throat, arthrosis, pain in the arm or leg
Uncommon: dizziness, constipation, itching
Rare: reduced platelet count
Frequency not known: kidney problems (which may require dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister)
Some patients have experienced the following side effects after taking metformin alone:
Very common: nausea, vomiting, diarrhea, stomach pain, and loss of appetite. These symptoms may appear when you start taking metformin and usually disappear
Common: metallic taste, decreased or low vitamin B12 levels in the blood (symptoms may include extreme fatigue, pain, and redness of the tongue, or pale or yellowish skin). Your doctor may request tests to determine the cause of your symptoms because some of them may also be caused by diabetes or other health problems unrelated to this medicine.
Very rare: hepatitis (a liver problem), hives, skin redness (rash), or itching
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and on the carton after EXP. The expiry date refers to the last day of the month indicated.
Do not store above 25 °C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help to protect the environment.
Composition of Efficib
Appearance and packaging of the product
Opaque blisters (PVC/PE/PVDC and aluminum). Packs of 14, 28, 56, 60, 112, 168, 180, and 196 film-coated tablets, multiple packs containing 196 (2 packs of 98) and 168 (2 packs of 84) film-coated tablets. Pack of 50 x 1 film-coated tablet in a precut unit dose blister.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
For further information about this medicine, please contact the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien MSD Belgium Tel: +32(0)27766211 dpoc_belux@msd.com | Lithuania UAB Merck Sharp & Dohme Tel: +370 5 2780 247 dpoc_lithuania@msd.com |
Luxembourg/Luxemburg MSD Belgium Tel: +32(0)27766211 dpoc_belux@msd.com | |
Czech Republic Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 dpoc_czechslovak@merck.com | Hungary MSD Pharma Hungary Kft. Tel: +36 1 888 5300 hungary_msd@merck.com |
Denmark MSD Danmark ApS Tel: +45 4482 4000 dkmail@msd.com | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com |
Germany MSD Sharp & Dohme GmbH Tel: +49 (0) 89 20 300 4500 medinfo@msd.de | Netherlands Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com |
Estonia Merck Sharp & Dohme OÜ Tel: +372 614 4200 dpoc.estonia@msd.com | Norway MSD (Norge) AS Tel: +47 32 20 73 00 medinfo.norway@msd.com |
Greece MSD Α.Φ.Ε.Ε. Tel: +30 210 98 97 300 dpoc_greece@merck.com | Austria Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 dpoc_austria@merck.com |
Spain Almirall, S.A. Tel: +34 93 291 30 00 info.spain@almirall.com | Poland MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 msdpolska@merck.com |
France MSD France Tel: +33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 inform_pt@merck.com |
Croatia Merck Sharp & Dohme d.o.o. Tel: +385 1 6611 333 croatia_info@merck.com | Romania Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 msdromania@merck.com |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfo_ireland@msd.com | Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 520 4201 msd_slovenia@merck.com |
Iceland Vistor ehf. Tel: +354 535 7000 | Slovak Republic Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 dpoc_czechslovak@merck.com |
Italy MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) dpoc.italy@msd.com | Finland MSD Finland Oy Tel: +358 (0)9 804 650 info@msd.fi |
Cyprus Merck Sharp & Dohme Cyprus Limited Tel: 800 00 673 (+357 22866700) cyprus_info@merck.com | Sweden Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@msd.com |
Latvia SIA Merck Sharp & Dohme Latvija Tel: +371 67025300 dpoc.latvia@msd.com |
Date of last revision of this leaflet:{MM/AAAA}.
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.